| Business Summary | | Orchid
Biociences,
Inc.
is
engaged
in
the
development
and
commercialization
of
technologies,
products
and
services
designed
to
measure
and
use
information
related
to
genetic
diversity.
The
Company
expects
its
proprietary
technologies
to
facilitate
and
potentially
accelerate
the
medical
utility
of
single
nucleotide
polymorphisms
(SNPs),
the
most
common
form
of
genetic
diversity.
The
Company's
diverse
line
of
products
for
SNP
scoring
includes
hardware,
wetware
consumable
kits
and
SNP
scoring
and
pharmacogenetic
services.
The
Company's
services
are
provided
through
its
high
throughput
MegaSNPatron
facility
and
at
its
GeneScreen
and
Cellmark
clinical
DNA
testing
facilities. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Orchid
Biosciences
is
engaged
in
the
development
of
technologies,
products
and
services
designed
to
measure
and
use
information
related
to
genetic
diversity.
For
the
six
months
ended
6/01,
revenues
increased
53%
to
$12.4
million.
Net
loss
applicable
to
Common
decreased
53%
to
$25.8
million.
Results
reflect
placements
of
SNPstream
25
thousand
instrument
systems
and
sales
of
SNPware
consumable
kits.
Lower
loss
also
reflects
the
absence
of
$29.6
million
in
Preferred
dividends. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Dale Pfost, Ph.D, 44 Chairman,
Pres, CEO | $715K | -- | Donald Marvin, 48 COO,
Chief Financial Officer, Sr. VP, Sec. | 508K | $337K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|